Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India.

Revenue projections:

Revenue projections for MANKIND
Revenue projections for MANKIND

Revenues for Mankind Pharma Limited are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 1.14300
forwardPE 34.04672
debtToEquity 53.89200
earningsGrowth -0.24000
revenueGrowth 0.20200
grossMargins 0.69782
operatingMargins 0.18920
trailingEps 42.36000
forwardEps 61.90318

MANKIND's current ratio, being 1.143, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, MANKIND is well-equipped to meet its immediate financial obligations without any difficulties.
MANKIND's low growth in both earnings and revenue indicates potential profit shrinkage. This downward trend could be a sign of weakening financial health, signaling challenges for the company's future profitability.
MANKIND's negative gross and operating margins suggest that the company is currently facing financial difficulties, as it is unable to cover production and operational costs. This could result in significant losses if not addressed.
With a forward EPS greater than its trailing EPS, Mankind Pharma Limited is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for MANKIND
Price projections for MANKIND

The price of Mankind Pharma Limited has consistently been close to the lower limit of expectations. This trend may point to challenges in the company's performance, leading to concerns about its future growth potential.

Recommendation changes over time:

Recommendations trend for MANKIND
Recommendations trend for MANKIND


Analysts have maintained a buy bias for Mankind Pharma Limited, which could prompt investors to consider the stock as a viable investment. With this positive outlook, Mankind Pharma Limited is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.